Neurocrine Biosciences and Takeda Amend Partnership to Develop and Commercialize Osavampator in Japan

Shots:

• Neurocrine & Takeda have revised their 2020 collaboration to develop & commercialize osavampator (NBI-1065845/TAK-653), which originally granted Neurocrine exclusive license to osavampator, NBI-1070770, & the GPR139 antagonist program
• As per the amendment, Neurocrine will get exclusive rights to develop & market osavampator to treat major depressive disorder (MDD) globally, while Takeda will reacquire the rights in Japan; both will share development cost in their respective regions and eligible to receive royalties
• Osavampator is an AMPA positive allosteric modulator developed by Neurocrine & Takeda to treat MDD. Following the FDA meeting on the P-II (SAVITRI) trial, a P-III trial will begin in H1’25

Ref: Prnewswire | Image: Neurocrine & Takeda

Related News:- Neurocrine’s Crenessity (Crinecerfont) Secures the US FDA’s Approval to Treat Adults and Pediatrics with Congenital Adrenal Hyperplasia (CAH)

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com